Drug Profile
Anti-Human-Carcinoma-Antigen monoclonal antibody
Alternative Names: Anti-human carcinoma antigen monoclonal antibodyLatest Information Update: 04 Apr 2003
Price :
$50
*
At a glance
- Originator Epigen; Medarex
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
- 28 Nov 2000 New profile
- 28 Nov 2000 Preclinical development for Prostate cancer in USA (Unknown route)